Roche Plans New Elevidys Study to Meet EU Approval Standards

Roche has announced a fresh clinical push for its gene therapy as it rolls out a new Elevidys study aimed at addressing concerns raised by European regulators.

The move comes after the therapy failed to secure approval in Europe, prompting the company to refine its approach and generate stronger evidence for its use in treating Duchenne muscular dystrophy (DMD).

The newly planned trial is a late-stage study designed in direct response to feedback from the European Medicines Agency.

Regulators had previously flagged safety risks and questioned whether the benefits of the therapy clearly outweighed those risks. Reports of patient deaths linked to treatment further intensified scrutiny, making it critical for Roche to revisit its data strategy.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

"Our confidence is rooted in robust long-term data showing the durable efficacy and safety of Elevidys, alongside the experience of treating more than a thousand ambulatory boys worldwide," Roche's Chief Medical Officer and Head of Global Product Development Levi Garraway said.

With this Elevidys study, Roche is focusing on delivering more robust and controlled clinical evidence. The goal is to better demonstrate both safety and effectiveness, particularly in a way that aligns with European regulatory expectations. The study is expected to play a key role in determining whether the therapy can eventually gain approval in the region.

Elevidys, developed by Sarepta Therapeutics, is already approved in the United States, where it has shown promise in slowing the progression of DMD, a rare genetic disorder that leads to progressive muscle degeneration. Roche holds the rights to commercialize the therapy outside the U.S., making Europe a crucial market for its expansion plans.

The outcome of this new trial could shape the future of gene therapies in Europe. A successful result would not only strengthen Roche’s position but also widen access for patients in need of new treatment options. However, failure to address safety concerns could delay progress and raise further questions about the therapy’s long-term viability.